Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy

Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 410

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 358

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 307

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 284

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 268

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Hamanishi, J., Takeshima, N., Katsumata, N., Ushijima, K., Kimura, T., Takeuchi, S., Matsumoto, K., Ito, K., Mandai, M., Nakai, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00334 · Cited by 218

Heterogeneity and treatment landscape of ovarian carcinoma

Veneziani, A. C., González-Ochoa, E., Alqaisi, H. A., Madariaga, A., Bhat, G. R., Rouzbahman, M., Sneha, S., & Oza, A. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00819-1 · Cited by 228

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

Havasi, A. D., Cainap, S. S., Havasi, A. T., & Cainap, C. I. (2023) · Medicina · doi:10.3390/medicina59030544 · Cited by 152

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., & Xu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114109 · Cited by 125

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach

Ghisoni, E., Morotti, M., Sarivalasis, A., Grimm, A. J., Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00937-4 · Cited by 131

The complementarity of DDR, nucleic acids and anti-tumour immunity

Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 117

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 113

PARP Inhibitors in Cancer Diagnosis and Therapy

Chan, C. Y., Tan, K. V., & Cornelissen, B. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2766 · Cited by 109

Interfaces between cellular responses to DNA damage and cancer immunotherapyPreprint

Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 96

New approaches for targeting platinum-resistant ovarian cancer

McMullen, M., Madariaga, A., & Lheureux, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.013 · Cited by 88

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives

Maiorano, B. A., Maiorano, M. F. P., Lorusso, D., & Maiello, E. (2021) · Cancers · doi:10.3390/cancers13174438 · Cited by 84

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance

Kanev, P.-B., Atemin, A., Stoynov, S., & Aleksandrov, R. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.001 · Cited by 89

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities

Garlisi, B., Lauks, S., Aitken, C., Ogilvie, L. M., Lockington, C., Petrik, D., Eichhorn, J. S., & Petrik, J. (2024) · Current Oncology · doi:10.3390/curroncol31070283 · Cited by 91

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer

Seitz, S., Dreyer, T. F., Stange, C., Steiger, K., Bräuer, R., Scheutz, L., Multhoff, G., Weichert, W., Kiechle, M. B., Magdolen, V., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01763-0 · Cited by 76

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma

Truxová, I., Cibula, D., Špíšek, R., & Fucikova, J. P. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005968 · Cited by 80

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers

Lee, E. K., & Konstantinopoulos, P. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944116 · Cited by 72

Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

Dominici, C., Sgarioto, N., Yu, Z., Sesma-Sanz, L., Masson, J., Richard, S., & Raynal, N. J. ‐. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01037-1 · Cited by 66

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis

Zhu, J., Yan, L., & Wang, Q. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00862-5 · Cited by 66

Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy

Peng, X., Pan, W., Jiang, F., Chen, W., Qi, Z., Peng, W., & Chen, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106529 · Cited by 65

Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies

Klemba, A., Bodnar, L., Waś, H., Brodaczewska, K. K., Wcisło, G., Szczylik, C. A., & Kiéda, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249492 · Cited by 59

Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents

Martorana, F., da Silva, L. A., Sessa, C., & Colombo, I. (2022) · Cancers · doi:10.3390/cancers14040953 · Cited by 61

PARP Inhibitors in Breast and Ovarian Cancer

Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies

Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52

Driving Immune Responses in the Ovarian Tumor Microenvironment

Ning, F., Cole, C. B., & Annunziata, C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604084 · Cited by 51

PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway

Biegała, Ł., Gajek, A., Marczak, A., & Rogalska, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188633 · Cited by 50

Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models

Wang, S., Chang, C.-W. M., Huang, J., Zeng, S., Zhang, X., Hung, M., & Hou, J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166841 · Cited by 50

PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers

Wu, T., Tang, C., Tao, R., Yong, X., Jiang, Q., & Feng, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693881 · Cited by 45

MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc

Anastasiadou, E., Messina, E., Sanavia, T., Mundo, L., Farinella, F., Lazzi, S., Megiorni, F., Ceccarelli, S., Pontecorvi, P., Marampon, F., et al. (2021) · Cells · doi:10.3390/cells10030519 · Cited by 45

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

de Jong, F. C., Rutten, V. C., Zuiverloon, T. C. M., & Theodorescu, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062800 · Cited by 44

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations

Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 46

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data

Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 45

A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade

Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 42

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints

Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44

Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies

Jia, H., Jiang, L., Shen, X., Ye, H., Li, X., Zhang, L., Hu, Y., Song, D., Jia, H., & Wang, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02397-5 · Cited by 49

PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Carro, M. L. F., Uzuner, E., Mole, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41737-1 · Cited by 42

Advancing cancer therapy: new frontiers in targeting DNA damage response

Qian, J., Liao, G., Chen, M., Peng, R., Yan, X., Du, J., Huang, R., Pan, M., Lin, Y., Gong, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474337 · Cited by 44

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Freyer, G., Floquet, A., Trédan, O., Carrot, A., Langlois‐Jacques, C., Lopez, J., Selle, F., Abdeddaim, C., Leary, A. F., Dubot, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45974-w · Cited by 41

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer

Sprooten, J., Vankerckhoven, A., Vanmeerbeek, I., Borràs, D., Berckmans, Y., Wouters, R., Laureano, R. S., Baert, T., Boon, L., Landolfo, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003609 · Cited by 38

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises

Pham, M. M., Ngoi, N. Y. L., Peng, G., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.004 · Cited by 38

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Toulmonde, M., Brahmi, M., Giraud, A., Chakiba, C., Bessede, A., Kind, M., Toulza, E., Pulido, M., Albert, S., Guégan, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2258 · Cited by 36

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Hollis, R. L., Meynert, A. M., Michie, C. O., Rye, T., Churchman, M., Hallas-Potts, A., Croy, I., McCluggage, W. G., Williams, A. R. W., Bartos, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0368 · Cited by 37

DNA Repair and Signaling in Immune-Related Cancer Therapy

Kakoti, S., Sato, H., Laskar, S. S., Yasuhara, T., & Shibata, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00205 · Cited by 36

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073871 · Cited by 39

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

Gordhandas, S., Manning‐Geist, B. L., Henson, C. E., Iyer, G., Gardner, G. J., Sonoda, Y., Moore, K. N., Aghajanian, C. A., Chui, M. H., & Grisham, R. N. (2022) · Scientific Reports · doi:10.1038/s41598-021-04618-5 · Cited by 34

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Xie, Y., Xiao, D., Li, D., Peng, M., Peng, W., Duan, H., & Yang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441222 · Cited by 35

Ovarian cancer targeted therapy: current landscape and future challenges

Wang, G., Yang, H., Wang, Y., & Qin, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1535235 · Cited by 39

Adoptive T cell therapy for ovarian cancer

Gitto, S. B., Ihewulezi, C., & Powell, D. J. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.04.001 · Cited by 31

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 32

Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes

Ullah, A., Chen, Y., Singla, R. K., Cao, D., & Shen, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107213 · Cited by 31

New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions

Zhang, C., Sheng, Y., Sun, X., & Wang, Y. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10113-2 · Cited by 33

The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions

Xie, J., Huang, H., Li, X., Ouyang, L., Wang, L., Liu, D., Wei, X., Tan, P., Tu, P., & Hu, Z. (2023) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2350074x · Cited by 29

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Kim, Y., Park, B., Kim, J., Kim, B. G., Kim, S. W., Kim, H. S., Choi, C. H., Lim, M. C., Ngoi, N. Y. L., Tan, D. S. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40829-2 · Cited by 29

C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer

Li, X., Poire, A., Jeong, K. J., Zhang, D., Ozmen, T. Y., Chen, G., Sun, C., & Mills, G. B. (2024) · Nature Communications · doi:10.1038/s41467-024-48637-y · Cited by 31

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

Konstantinopoulos, P. A., & Cannistra, S. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00571 · Cited by 28

Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?

Bonadio, R. C., Tarantino, P., Testa, L., Punie, K., Pernas, S., Barrios, C. H., Curigliano, G., Tolaney, S. M., & Barroso‐Sousa, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102459 · Cited by 28

Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer

Liu, C., Qian, X., Yu, C., Xia, X., Li, J., Li, Y., Xie, Y., Gao, G., Song, Y., Zhang, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216642 · Cited by 28

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies

Wang, L., Zhang, Q., Wang, X., Dong, Z., Liu, S., Wang, Q., Zhang, Z., & Xing, J. (2025) · Biomarker Research · doi:10.1186/s40364-025-00818-7 · Cited by 32

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

Veneziani, A. C., Scott, C. L., Wakefield, M. J., Tinker, A. V., & Lheureux, S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231157644 · Cited by 30

Overcoming PARP inhibitor resistance in ovarian cancer

Pina, P. S., & Lheureux, S. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003698 · Cited by 27

Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer

Moffitt, L. R., Karimnia, N., Wilson, A., Stephens, A. N., Ho, G., & Bilandzic, M. (2024) · Current Oncology · doi:10.3390/curroncol31120592 · Cited by 25

Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors

Elkin, R., Oh, J. H., Liu, Y. L., Selenica, P., Weigelt, B., Reis-Filho, J. S., Zamarin, D., Deasy, J. O., Norton, L., Levine, A. J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00259-9 · Cited by 27

Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives

Awada, A., Ahmad, S., McKenzie, N. D., & Holloway, R. W. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s335936 · Cited by 25

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer

Clark, C. A., & Yang, E. S.-H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703802 · Cited by 24

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future

Maiorano, B. A., Maiorano, M. F. P., & Maiello, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1162665 · Cited by 24

Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer

Zhao, L., Chen, X., Wu, H., He, Q., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115724 · Cited by 25

Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies

Li, T., Wang, X., Qin, S., Chen, B., Yi, M., & Zhou, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114712 · Cited by 24

Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy

Vathiotis, I. A., Johnson, J. M., & Argiris, A. E. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102192 · Cited by 23

Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed

Hu, X., Bian, C., Zhao, X., & Yi, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034903 · Cited by 21

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

Barve, M. A., Aaron, P. A., Manning, L., Bognar, E., Wallraven, G., Horvath, S., Stanbery, L., & Nemunaitis, J. J. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221110501 · Cited by 21

Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC

Jiang, R., Yang, L., Liu, X., Xu, Y., Han, L., Chen, Y., Gao, G., Wang, M., Su, T., Li, H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.024 · Cited by 22

The Complement System in Ovarian Cancer: An Underexplored Old Path

Senent, Y., Ajona, D., González-Martı́n, A., Pı́o, R., & Tavira, B. (2021) · Cancers · doi:10.3390/cancers13153806 · Cited by 19

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer

Xu, Y., Zuo, F., Wang, H., Jing, J., & He, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1045957 · Cited by 19

Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects

Bronger, H. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1475-4335 · Cited by 19

Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers

Koshrovski‐Michael, S., Ajamil, D. R., Dey, P., Kleiner, R., Tevet, S., Epshtein, Y., Buzhor, M. G., Khoury, R., Pozzi, S., Shenbach‐Koltin, G., et al. (2024) · Science Advances · doi:10.1126/sciadv.adr4762 · Cited by 20

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis

Yin, R., Zhang, P., Zhang, T., Zhang, T., & Yin, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151871 · Cited by 17

Advances in immunotherapy for gynecological malignancies

Tu, M., & Xu, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104063 · Cited by 19

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

Friedlander, M. L., Mileshkin, L., Lombard, J. M., Frentzas, S., Gao, B., Wilson, M. K., Meniawy, T. M., Baron-Hay, S. E., Briscoe, K. P., McCarthy, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02349-0 · Cited by 18

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen, J., Yang, L., Ma, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412328 · Cited by 18

PHGDH Inhibitor CBR‐5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β‐Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib

Zhang, X., Sun, M., Jiao, Y., Lin, B., & Yang, Q. F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9029544 · Cited by 17

Limitations and potential of immunotherapy in ovarian cancer

Kumar, S., Acharya, S., Karthikeyan, M., Biswas, P., & Kumari, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292166 · Cited by 18

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality

Turinetto, M., Scotto, G., Tuninetti, V., Giannone, G., & Valabrega, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689829 · Cited by 19

Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor

Yi, X.-F., Gao, R.-L., Sun, L., Wu, Z.-X., Zhang, S., Huang, L., Han, C., & Ma, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114770 · Cited by 20

Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045

Kim, Y., Joung, J., Park, E., Kim, J., Lee, J. B., Lim, J., Kim, S., Choi, C. H., Kim, H. S., Chung, J., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34696 · Cited by 15

Immunotherapy for Ovarian Cancer: Disappointing or Promising?

Deng, M., Tang, F., Chang, X., Liu, P., Ji, X., Hao, M., Wang, Y., Yang, R., Ma, Q., Zhang, Y., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00986 · Cited by 18

Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application

Xie, H., Wang, W., Qi, W.-C., Jin, W., & Xia, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661115 · Cited by 17

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 15

Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer

Juncheng, P., Joseph, A., Lafarge, A., Martins, I., Obrist, F., Pol, J. G., Saavedra, E., Li, S., Sauvat, A., Cerrato, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004280 · Cited by 14

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors

Funingana, I.-G., Bedia, J. S., Huang, Y.-W., Delgado‐González, A., Donoso, K., Gonzalez, V. D., Brenton, J. D., Ashworth, A., & Fantl, W. J. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-022-00979-9 · Cited by 14

Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes

Zajac, K. K., Malla, S., Babu, R. J., Raman, D., & Tiwari, A. K. (2023) · Cancer Reports · doi:10.1002/cnr2.1779 · Cited by 13

Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer

Tabata, J., Huang, T., Giudice, E., Ibanez, K. R., Nair, J. R., Conlon, K., Solarz, B. B., Bolanos, V., Lipkowitz, S., Redd, B. A., et al. (2025) · Cancer Research · doi:10.1158/1538-7445.ovarian25-pr004

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Lee, J.-M., Annunziata, C. M., Houston, N. D., Kohn, E. C., Lipkowitz, S., Minasian, L. M., Nichols, E. H., Trepel, J. B., Trewhitt, K., Zia, F. Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy285.145 · Cited by 35

Phase 2 evaluation of olaparib in combination with durvalumab and tremelimumab in recurrent epithelial ovarian cancer with BRCA mutation or homologous recombination deficiency

Zsíros, E., Chodon, T., Matsuzaki, J., Mager, K. L., Frederick, P., Lele, S., DeJohn, C. R., Lamacki, A., Wang, C., Tsuji, T., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.01.241

Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study

Adams, S. F., Gimotty, P. A., Rutledge, T. L., O’Malley, D. M., Ring, K. L., Wenham, R. M., Finkelstein, K., Lokich, E., Falcon, D. M., Yeckes, A. R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78395-y

Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404).

Lee, J., Zimmer, A. D. S., Lipkowitz, S., Annunziata, C. M., Ho, T. W., Chiou, V. L., Minasian, L. M., Houston, N. D., Ekwede, I., & Kohn, E. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3015 · Cited by 31